UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

PloS one, 2017-10, Vol.12 (10), p.e0186106-e0186106

2017

Volltextzugriff (PDF)

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma

PloS one, 2019-11, Vol.14 (11), p.e0225509

2019

Volltextzugriff (PDF)

Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years

European journal of cancer (1990), 2013-04, Vol.49 (6), p.1216-1225

2013

Volltextzugriff (PDF)

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

The lancet oncology, 2014-10, Vol.15 (11), p.1254-1262

2014

Volltextzugriff (PDF)

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

Investigational new drugs, 2016-06, Vol.34 (3), p.290-299

2016

Volltextzugriff (PDF)

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

Journal of clinical oncology, 2006-12, Vol.24 (34), p.5441-5447

2006

Volltextzugriff (PDF)

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients

Cancer chemotherapy and pharmacology, 2016-02, Vol.77 (2), p.375-383

2016

Volltextzugriff (PDF)

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1220-1226

2009

Volltextzugriff (PDF)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2018-11, Vol.82 (5), p.757-766

2018

Volltextzugriff (PDF)

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib

Journal of thoracic oncology, 2011-11, Vol.6 (11), p.1962-1963

2011

Volltextzugriff (PDF)

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

European journal of cancer (1990), 2013-09, Vol.49 (13), p.2815-2822

2013

Volltextzugriff (PDF)

Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors

European journal of cancer (1990), 2012-01, Vol.48 (1), p.61-67

2012

Volltextzugriff (PDF)

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4007-4014

2015

Volltextzugriff (PDF)

Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2008-07, Vol.3 (7), p.728-734

2008

Volltextzugriff (PDF)

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma

European journal of cancer (1990), 2012-11, Vol.48 (16), p.2983-2992

2012

Volltextzugriff (PDF)

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

BMC cancer, 2013-04, Vol.13 (1), p.207-207, Article 207

2013

Volltextzugriff (PDF)

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

Journal of clinical oncology, 2014-12, Vol.32 (35), p.4012-4019

2014

Volltextzugriff (PDF)

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit

European journal of cancer (1990), 2017-04, Vol.75, p.56-62

2017

Volltextzugriff (PDF)

How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? – A short report

European journal of cancer (1990), 2012-09, Vol.48 (14), p.2163-2165

2012

Volltextzugriff (PDF)

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation

European journal of cancer (1990), 2014-11, Vol.50 (16), p.2771-2782

2014

Volltextzugriff (PDF)

Paraneoplastic Erythema Annulare Centrifugum Eruption (PEACE) Associated With Metastatic Colorectal Adenocarcinoma

Curēus (Palo Alto, CA), 2021-10

2021

Volltextzugriff (PDF)

Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy

Journal of thoracic oncology, 2010-09, Vol.5 (9), p.1397-1403

2010

Volltextzugriff (PDF)

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Journal of thoracic oncology, 2020-10, Vol.15 (10), p.1647-1656

2020

Volltextzugriff (PDF)

Topotecan for the treatment of small-cell lung cancer

Expert review of anticancer therapy, 2007-06, Vol.7 (6), p.795-801

2007

Volltextzugriff (PDF)

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)

European journal of cancer (1990), 2015-08, Vol.51 (12), p.1511-1528

2015

Volltextzugriff (PDF)

1 – 25 von 30.245

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27.257)
Mit Volltextzugriff
(24.601)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(21.332)
Life Sciences & Biomedicine
(19.246)
Humans
(15.524)
Female
(9.881)
Male
(8.850)
Biological And Medical Sciences
(8.071)
Medical Sciences
(6.411)
Adult
(5.718)
Middle Aged
(5.070)
Animals
(4.259)
Aged
(3.770)
Adolescent
(2.722)
Child
(2.265)
Fundamental And Applied Biological Sciences. Psychology
(2.082)
Risk Factors
(1.978)
Social Sciences
(1.738)
General & Internal Medicine
(1.708)
Oncology
(1.626)
Infectious Diseases
(1.557)
Immunology
(1.538)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(19.146)
EZB Free E-Journals
(14.009)
Journals@Ovid Complete
(13.199)
Ingenta
(11.999)
Publisher or Other Site
(9.870)
Elsevier ScienceDirect Journals Complete
(6.118)
IngentaConnect Journals
(4.271)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(3.922)
Wiley Online Library - AutoHoldings Journals
(3.807)
Wiley Online Library Full Collection 2018
(2.690)
Jstor Complete Legacy
(2.562)
Oxford University Press Journals Current
(2.057)
Springer Online Journals
(1.658)
Oxford Journals 2020 Medicine
(1.645)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.057)
Nature Journals Online
(989)
Applied Social Sciences Index & Abstracts (ASSIA)
(829)
Taylor & Francis Journals Auto-Holdings Collection
(829)
SAGE Journals
(827)
Taylor & Francis:Master (3349 titles)
(824)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma

Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit

How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? – A short report

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation

Paraneoplastic Erythema Annulare Centrifugum Eruption (PEACE) Associated With Metastatic Colorectal Adenocarcinoma

Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Topotecan for the treatment of small-cell lung cancer

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)

Suchergebnisse filtern